| Original language | English (US) |
|---|---|
| Pages (from-to) | 28-33 |
| Number of pages | 6 |
| Journal | ACC Current Journal Review |
| Volume | 13 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2004 |
ASJC Scopus subject areas
- Nursing(all)
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Arrhythmogenic right ventricle dysplasia/cardiomyopathy. / Nasir, Khurram; Calkins, Hugh.
In: ACC Current Journal Review, Vol. 13, No. 6, 06.2004, p. 28-33.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Arrhythmogenic right ventricle dysplasia/cardiomyopathy
AU - Nasir, Khurram
AU - Calkins, Hugh
N1 - Funding Information: The Johns Hopkins ARVD program is funded by a private grant from the Bogle Foundation. This study is also supported by National Institutes of Health Research Grant 1 UO1 HL65594-01A1. Funding Information: A large number of questions remain unanswered regarding the diagnosis and treatment of ARVD/C. For example, it remains uncertain how to clearly exclude the diagnosis of ARVD/C in patients with a mild form of the disease and in relatives of affected individuals. The natural history of the disease has also not been well defined. Regarding treatment, further research is needed to better define which patients suspected of having ARVD/C benefit from placement of an ICD. Further work is also needed to identify more of the genes that cause ARVD/C. This information will greatly facilitate diagnosis of the disease and would also allow for genotype/phenotype correlations. In addition, the identification of the specific genetic defects may ultimately have specific therapeutic implications for gene therapy. The ongoing Multidisciplinary Study of Right Ventricular Dysplasia, which is a multicenter, collaborative study to investigate the cardiac, clinical and genetic aspects of ARVD funded by a grant from the National Institutes of Health and the National Heart Lung and Blood Institute should help address some of these questions. This study will follow patients with ARVD and their family members for the next 5 years, accumulating information in a centralized manner to answer some of the important questions regarding the course, prognosis and best treatment for ARVD/C. More information concerning this registry is available at www.arvd.com and www.arvd.com . Hopefully these efforts and others in the years ahead will provide answers to the many still unanswered questions concerning ARVD/C. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2004/6
Y1 - 2004/6
UR - http://www.scopus.com/inward/record.url?scp=3342957399&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3342957399&partnerID=8YFLogxK
U2 - 10.1016/j.accreview.2004.06.002
DO - 10.1016/j.accreview.2004.06.002
M3 - Review article
AN - SCOPUS:3342957399
VL - 13
SP - 28
EP - 33
JO - ACC Current Journal Review
JF - ACC Current Journal Review
SN - 1062-1458
IS - 6
ER -